Under the terms of the agreement, Nephros and BHC Medical will work together to promote the sale and distribution of Nephros’ OLpur MD 220 filters through various advertising and promotional campaigns and by working with and training BHC’s sales and support staff.

Nephros has completed the patient treatment phase of the US clinical trial evaluation of the OLpur H2H module and OLpur MD 220 filter during the second quarter of 2008. The company has submitted the clinical data to the FDA with the 510(k) application for US marketing approval of these products in November 2008.

Ernest Elgin, president and CEO of Nephros, said: “Bellco Medical is an ideal partner for the Canadian market. They are a leading provider of End-Stage Renal Disease treatment systems who embrace leading-edge dialysis technologies such as our OLpur MD 220 HDF therapy.”

Denis Carrier, CEO of BHC Medical, said: “We are excited for the opportunity to present the OLpur MD220 to the Canadian dialysis community, and we anticipate it being a crucial component of the therapy package that we promote to clinicians to conduct the advanced dialysis modalities available presently.”

Canada-based BHC Medical offers a complete array of advanced medical devices, consumables, water treatment technologies, disinfectants and pharmaceuticals.